Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corneal Transplantation Clear all

Conditions: Corneal Transplant
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cataract, Corneal Disease
Interventions: LenSx Laser modified disposable contact lens; Device
Lead sponsor: LenSx Lasers Inc.; Industry
Eligibility: 24 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Ripasudil hydrochloride hydrate 0.4% ophthalmic solution; Drug
Lead sponsor: Marian Macsai, MD; Other
Eligibility: 18 Years to 91 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Fuchs' Dystrophy, Corneal Edema
Interventions: loteprednol etabonate, prednisolone acetate 1%; Drug
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fuchs' Endothelial Dystrophy
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema
Interventions: Endothelial keratoplasty, PRGF; Procedure · Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Indianapolis, Indiana

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Corneal Transplantation
Interventions: EndoSaver™ Corneal Endothelium Delivery Instrument; Device
Lead sponsor: Ocular Systems, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Interventions: Dextenza 0.4Mg Ophthalmic Insert; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Corneal Transplant, Corneal Crosslinking, Healthy Eyes
Interventions: BOSS Imaging; Diagnostic Test
Lead sponsor: Intelon Optics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Corneal Neovascularization
Interventions: Subconjunctival aflibercept, Placebo: Standard of care only; Drug · Other
Lead sponsor: Balamurali Ambati; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Corneal Diseases, Cornea Transplant
Interventions: LX201, Placebo; Drug · Other
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more

Conditions: Complications of Corneal Transplant
Interventions: Corneal donor storage in Optisol GS media solution, Life 4°C solution for cornea storage; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Grand Rapids, Michigan • Cleveland, Ohio + 1 more

Conditions: Fuchs Dystrophy, Corneal Edema
Interventions: Corneal transplantation; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Keratoconus
Interventions: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light; Drug
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
Interventions: Adalimumab Injection; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Corneal Transplantation
Interventions: Deep Lamellar Endothelial Keratoplasty: Small Incision Technique; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 95 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Corneal Blindness
Interventions: KeraKlear Non-Penetrating Keratoprosthesis; Device
Lead sponsor: KeraMed, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Irvine, California • Edgewood, Kentucky • Boston, Massachusetts + 1 more

Conditions: Presbyopia
Interventions: Optimal laser keratoplasty; Device
Lead sponsor: VIS, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Boca Raton, Florida • South Dartmouth, Massachusetts • Teaneck, New Jersey + 1 more

Conditions: Corneal Transplantation
Interventions: sodium hyaluronate; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Corneal Neovascularization, Corneal Graft Failure
Interventions: Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions: Gamunex-C; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Corneal Neovascularization, Corneal Graft Failure
Interventions: Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York

Conditions: Fuchs' Endothelial Dystrophy, Cataract
Interventions: Netarsudil 0.02% Ophthalmic Solution; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 50 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Neovascularization Patterns in Corneal Graft Rejection

New Disposable Contact Lens Patient Interface For The Lensx Laser

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Plasma Rich in Growth Factors in Corneal Endothelial Transplantation

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Corneal Endothelium Delivery Instrument

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

A Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System

Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Life 4°C Versus Optisol in Corneal Storage Media

A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

Subconjunctival Humira for Boston Keratoprosthesis

Deep Lamellar Endothelial Keratoplasty: Small Incision Technique

A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity

Phase III Presbyopia Correction Using the VIS Opti-K™ System

A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty